CervoMed Inc. - CRVO Earnings per share for the last twelve months

CRVO (CervoMed Corporation) - company brandmark

Ultra-stringent FDA oversight and the complexities of neurological research create colossal barriers for CervoMed Inc. (CRVO). The trailing 12-month earnings per share, illustrated by this chart on GURU.Markets, demonstrates current resilience, where the value -2.77 represents the latest figure. Innovation efficiency relies on strict climate-controlled supply chains, while investor confidence is based on strict adherence to clinical asset validation schedules.

CRVO CervoMed Corporation Net earnings per share for the last 12 months (02/21/2024 - 11/17/2026)

Financial and market metric breakdowns for CervoMed Inc. (CRVO)

- share price and expert price forecast:
General company analysis:CervoMed, Inc. (CRVO)
Manufactured products of CervoMed Corporation

CervoMed Inc. (CRVO) business resilience to market shocks is driven by the potential for lifelong demand for degenerative brain disease therapies. Patent protection and the chronic nature of these pathologies establish a foundation for stable margins. Analyzing this 12-month EPS chart, an investor sees the net profit allocated per share over a rolling year. This metric strips the financial result of dilution distortions, reflecting the real efficiency of capital. Monitoring this trend allows for the timely detection of a gap between expectations and actual income.

Competitors of CervoMed Inc.

biogen.com - Net earnings per share (EPS TTM)|Earnings per share for the trailing year NBIX (Neurocrine)|RGC: Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Axsome Therapeutics Inc|ACAD (ACADIA Corp) - Net earnings per share (EPS TTM)|XENE: Earnings per share for the trailing year|Net earnings per share for the last 12 months VKTX (Viking Therapeutics, Inc.)|Net earnings per share (EPS TTM) Supernus Pharmaceuticals, Inc. (SUPN)|Catalyst Pharmaceuticals, Inc. - Net earnings per share for the last 12 months|Earnings per share for the last four quarters DNLI (Denali Therapeutics Inc)|Harmony Biosciences - Net earnings per share (EPS TTM)|Earnings per share for the trailing year BHVN (biohavenpharma.com)|AMLX: Net earnings per share (EPS TTM)|Trevi Therapeutics, Inc. - Earnings per share for the trailing year|PRAX (Praxis Corp) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Anavex Life Sciences AVXL|Net earnings per share (EPS TTM) CBLL|PRTA (prothena.com) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) ALEC (Alector Inc.)|Net earnings per share (EPS TTM) Annexon Biosciences ANNX|Omeros Corporation - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters Neurogene Therapeutics NGNE|ACIU: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Voyager Therapeutics, Inc. (VYGR)|Net earnings per share for the last 12 months NMRA|Net earnings per share for the last 12 months Scilex Holding (SCLX)|Net earnings per share (EPS TTM) TVGN|Net earnings per share for the last 12 months Alpha Cognition Inc ACOG|cogrx.com - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Inhibikase Therapeutics, Inc. IKT|SAVA - Earnings per share for the last twelve months|Net earnings per share for the last four quarters Assertio ASRT|Coya Therapeutics, Inc. (COYA) - Earnings per share for the last twelve months|Net earnings per share for the last 12 months VistaGen Therapeutics Inc|OVID (ovidrx.com) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months ABOS|Net earnings per share (EPS TTM) ATHE|CLNN - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months PepGen Inc PEPG|Net earnings per share for the last four quarters jupiterneurosciences.com (JUNS)|Relmada Therapeutics, Inc. - Net earnings per share (EPS TTM)|Earnings per share for the trailing year ANVS (annovisbio.com)|Grace Tx (GRCE) - Earnings per share for the last twelve months|Firefly Neuroscience (AIFF) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months Klotho Neurosciences Inc|neurosense-tx.com (NRSN) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Reviva Pharmaceuticals Holdings, Inc. (RVPH)|Net earnings per share (EPS TTM) MetaVia, Inc. (MTVA)|NeurAxis, Inc - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Helius Medical HSDT|PASG - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Neuphoria Therapeutics, Inc.|Minerva Neurosciences Inc (NERV) - Earnings per share for the last twelve months|Athira Pharma, Inc. - Earnings per share for the trailing year|ADXN (Addex) - Net earnings per share (EPS TTM)|Alzamend Neuro, Inc. - Earnings per one share for the last 12 months|Net earnings per share (EPS TTM) CYCN|PTIX - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months pasitheaclinics.com KTTA|Earnings per share for the trailing year CRGT|Avenue Therapeutics Inc - Net earnings per share (EPS TTM)|Brainstorm Cell Therapeutics, Inc. (BCLI) - Net earnings per share for the last 12 months|CARA: Net earnings per share (EPS TTM)|Chromocell - Earnings per share for the trailing year|ELYM (Eliem Therapeutics, Inc.) - Net earnings per share (EPS TTM)|ITCI (intracellulartherapies.com) - Earnings per share for the last four quarters|Earnings per share for the last twelve months Longboard Pharma (LBPH)|Marinus - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) NKGN (nkgenbiotech.com)|NeuroBo Pharma - Earnings per share for the last twelve months|Sage Therapeutics Inc. - Net earnings per share (EPS TTM)|Earnings per share for the trailing year SNPX (Synaptogenix, Inc.)|TRVN (trevena.com) - Net earnings per share for the last 12 months|Net earnings per share for the last 12 months Vigil Neuroscience Inc.|Earnings per share for the last twelve months Anew Medical|CERE: Earnings per share for the trailing year